PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer’s Disease: The Potential Role of a Novel Nano-Compound – the Transdermal Glutathione-Cyclodextrin Complex
Version 1
: Received: 26 June 2024 / Approved: 26 June 2024 / Online: 26 June 2024 (11:56:54 CEST)
How to cite:
Yutani, R.; Venketaraman, V.; Sheren, N. Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer’s Disease: The Potential Role of a Novel Nano-Compound – the Transdermal Glutathione-Cyclodextrin Complex. Preprints2024, 2024061841. https://doi.org/10.20944/preprints202406.1841.v1
Yutani, R.; Venketaraman, V.; Sheren, N. Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer’s Disease: The Potential Role of a Novel Nano-Compound – the Transdermal Glutathione-Cyclodextrin Complex. Preprints 2024, 2024061841. https://doi.org/10.20944/preprints202406.1841.v1
Yutani, R.; Venketaraman, V.; Sheren, N. Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer’s Disease: The Potential Role of a Novel Nano-Compound – the Transdermal Glutathione-Cyclodextrin Complex. Preprints2024, 2024061841. https://doi.org/10.20944/preprints202406.1841.v1
APA Style
Yutani, R., Venketaraman, V., & Sheren, N. (2024). Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer’s Disease: The Potential Role of a Novel Nano-Compound – the Transdermal Glutathione-Cyclodextrin Complex. Preprints. https://doi.org/10.20944/preprints202406.1841.v1
Chicago/Turabian Style
Yutani, R., Vishwanath Venketaraman and Nisar Sheren. 2024 "Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer’s Disease: The Potential Role of a Novel Nano-Compound – the Transdermal Glutathione-Cyclodextrin Complex" Preprints. https://doi.org/10.20944/preprints202406.1841.v1
Abstract
Oxidative stress (OS) occurs from excessive reactive oxygen species or a deficiency of antioxidants – primarily endogenous glutathione (GSH). There are many illnesses, from acute and post-COVID-19, diabetes, myocardial infarction, to Alzheimer’s disease, that are associated with OS. These dissimilar illnesses are in order, a viral infection, a metabolic disorder, an ischemic event, and a neurodegenerative disorder. OS may be an early initiator or a significant promotor of their progressive pathophysiologic processes. Consequently, addressing initial OS-related pathology may avoid subsequent severe and irreversible complications. Early intervention would modulate multiple factors, including cytokine stimulation, complement dysregulation, immuno-thrombosis, fibrosis, and autoimmunity. Past clinical studies that addressed OS have had equivocal results. It may be due to the use of ineffective antioxidants, an untimely delay in their use, or an inefficient delivery system. Experimental studies have used antioxidants that are not available for clinical trials. Although GSH can significantly reduce OS, its exogenous use is hampered by the lack of an effective delivery system. By incorporating GSH into cyclodextrin (CD) through nanotechnology, there is recent evidence that exogenous GSH can be delivered more effectively to prevent or mitigate injury from OS [1]. Future studies using the GSH/cyclodextrin (GC) complex will be needed to confirm its effectiveness and, hopefully, offer a path to treat many sub-optimally managed or currently untreatable illnesses.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
